Painchek PCK.ASX One to watch?

About to dip my toes into Painchek. I see Joshua Tree has this on his list this year. I was running a filter across all Aussie shares and this one turned up with a PLUS in all five of my indicators - MacD, RSI, Twiggs Momentum, Twiggs Trend and Twiggs Money Flow. They make an app that can asses pain using a smart phone fro those who cannot communicate well - currently dementia sufferers. Sales seem to be taking off. The same tech can be used on children too. Will buy a small quantity for watching purposes.

Had a mate ask me about this, He was told about it by a guy who's done rather well with his finances, as you say it's one to watch.

What software are using to analyse aussie shares??

Quote:

---

Originally Posted by Groovyll

What software are using to analyse aussie shares??

---

Incredible Charts.
https://www.incrediblecharts.com
http://thenudeinvestor.com/stock-cha...0of%20features.

Anyone else investing into PCK? I see Summerset is taking up the technology. PCK, we will need more investment to tackle to USA. The product is getting good testing in NZ, Australia and UK, some 2400 videos are done each day.

Another grant received, this time a small 400k offering from WA. This will assist developing the infant application. Painchek are very good at Not announcing deals to the market, I have never seen a company try to fly under the radar, crazy.

I received this yesterday so the date should be 8th July ,not February.
Should you miss the presentations it you can find it on Youtube in a few days time.


Topic
Share Cafe Webinar - Micro/Small Cap "Hidden Gems" Webinar
Description
This Free webinar gives viewers the opportunity to hear from, and engage with, a range of ASX listed micro/small cap "hidden gems"

Company presentations will come from:
Jason Stirbinskis, Los Cerros (ASX: LCL)
Philip Daffas, PainChek (ASX: PCK)
Paul Anderson, Orthocell Limited (ASX: OCC)
Matt Macfarlane, icetana (ASX: ICE)

Time: 12.30pm AEST
Day: Friday, 8 February 2022
Duration: ~ 1 hour

Each company will give a 10 min presentation, followed by 5 min of Q&A.

The webinar offers 1 hour of CPD accreditation (must supply organisation and title to receive).
Time
Jul 8, 2022 12:30 PM in Canberra, Melbourne, Sydney

https://sharecafe.us14.list-manage.c...4&e=338561e893

Another good announcement, Wales are getting on board.

Seems we are starting to get traction.

70,000 licences currently granted
Over 1.3m pain assessments done, up 31% from the previous quarter.

FDA in progress, good to see this market left to last. It will be the hardest to get right.

Low out goings circa 2mil per quarter
Sales revenue increasing 333k 10% increase from previous quarter.

Key points from latest quarterly.

64,000 global commercial beds contracted, a 127% increase compared to prior corresponding period
(PCP).

78% increase in cash receipts to $551,000 in Q3 FY23 vs PCP, with YTD cash receipts up 153% to
$1,504,000.

Cumulative Painchek pain assessments exceed 2,300,000 as of 31 March.

Circa 3500 pain assessments conducted daily.

PainChek is currently achieving 84% licence retention rates

PainChek is targeting US FDA clearance for market entry in 2024.

PainChek is now in communication with the Japanese regulatory authorities (PMDA) to determine
regulatory process and requirements.

Capital raise or finance needed in 3/6 months

Key points from latest quarterly.

96% increase in global contracted bed licences over prior year to 70,000 commercial licences across
more than 1,000 aged care facilities in ANZ, UK and initial sales in Canada.

85% client retention rate on annual renewal

A 90% increase in annual customer receipts to $2,241,000, with Q4 FY23 increasing 26% to $737,000 vs
PCP and up 33% vs Q3 FY23.

R&D incentive $1,049,000 was received in the quarter.

Cumulative PainChek pain assessments exceed 2,900,000 as of 30 June – an increase of 115% over the
previous year.

Depending on what numbers you use, this equates to 5000-6600 daily pain assessments.

Finance/CR will need to be sorted this quarter. Bring on the north American market and FDA approval.

Nice results out of Scotland,

after 12 weeks falls within the home had reduced by 75% and episodes of stress and distress had reduced by 42%